Compare Heron Therapeutics Inc (HRTX) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Invesco S&P 500 Low Volatility ETF — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Invesco S&P 500 Low Volatility ETF trades at $71.97 (market cap $7.00B). The key difference: Invesco S&P 500 Low Volatility ETF is far larger — about 94.5× Heron Therapeutics Inc's market cap, and Invesco S&P 500 Low Volatility ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Invesco S&P 500 Low Volatility ETF for 123 Days on average.
| HRTX | SPLV | |
|---|---|---|
Market Cap | $74.04M | $7.00B |
Volume | 3,668,095 | 1,622,563 |
Sector | Health | — |
52-Week High | $1.49 | $77.97 |
52-Week Low | $0.27 | $70.30 |
Typical Hold Time | 35 Days | 123 Days |
Enterprise Value | $180.78M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
SPLV trades at $71.22, down 0.71% with a bearish technical signal from moving averages. The ETF's sector overweights in Utilities, Real Estate, and Financials have contributed to underperformance versus the S&P 500. Recent dividend payments of $0.14 per share were distributed in July and September 2026, while technical indicators show mixed signals with neutral RSI readings but strong bearish ADX momentum.
The outlook remains challenged by sector headwinds and unappealing growth-adjusted valuation at 19.5x P/E. Key risks include continued underperformance relative to broader market and sensitivity to interest rate movements. Opportunities exist for investors seeking low-volatility exposure during market uncertainty, though near-term catalysts appear limited.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
